Abstract: Measurement of circulating parathyroid hormone (PTH) levels is essential for optimal management of mineral and bone disorders (MBD) in chronic kidney disease (CKD) patients. There are two major types of PTH assays currently in use: intact parathyroid hormone (i-PTH) and whole PTH (w-PTH) assays. The i-PTH assay is the current standard, and considerable information regarding the management of CKD-MBD has been obtained with this method. However, several limitations have been found with the i-PTH assay. One limitation is that i-PTH assay also measures fragments other than fulllength PTH (1-84). Another limitation is the existence of multiple readout methods of the i-PTH assay. The w-PTH assay is theoretically ideal because it exclusively detects full-length PTH (1-84). However, clinical data proving the advantages of w-PTH measurement are not sufficient. For uremic patients, Kidney Disease Improving Global Outcomes suggest that PTH levels should be maintained within approximately two to nine times the upper normal limit of the i-PTH assays. The most critical issue in the evaluation of PTH levels is the lack of definitive PTH assay method. Evidence-based recommendations on clinical management goals of PTH are warranted.
The number of patients with chronic kidney disease (CKD) is increasing worldwide. Although effective treatments and management of CKD patients have been developed, a considerable proportion of these patients unfortunately progress to end stage renal disease (ESRD). The patients with ESRD often manifest mineral and bone disorders (MBD). Secondary hyperparathyroidism (SHPT) is a common complication in CKD and is characterized by excessive synthesis of parathyroid hormone (PTH) and parathyroid hyperplasia (1) . Hyperphosphatemia, decreased calcitriol, and the resultant slight decrease in serum calcium are considered to be the main contributors to the pathogenesis of SHPT (2) . In addition, recent investigations have identified fibroblast growth factor 23 as another factor in this pathogenesis (3) . Accurate measurement of circulating PTH levels is essential for the optimal management of CKD-MBD patients.
Parathyroid hormone is a single-chain polypeptide hormone consisting of 84 amino acids with an approximate molecular weight of 9500 Da (Fig. 1) , and is secreted by the chief cells of the parathyroid gland (4). It is a major regulator of bone remodeling and participates in the homeostatic response to alterations in plasma calcium concentrations (5, 6) . In patients with CKD, PTH levels are used widely as a surrogate marker in the assessment of the skeletal and mineral disorders associated with CKD or CKD-MBD (7, 8) . The type 1 PTH/PTHrP receptor mediates the classical biological effects of PTH on the bones and the kidney (9, 10) .
In this article, we first briefly describe the history of PTH assays and discuss the merits and demerits of each PTH assay method. Next, we provide an overview of clinical application of PTH assays in CKD patients and of several published guidelines for the optimal management of MBD in CKD patients. Finally, we describe some current topics in PTH measurement.
HISTORY OF PARATHYROID HORMONE ASSAY
The first-generation PTH radioimmunoassays were developed in the 1960s (11, 12) . In the 1970s, their relatively poor sensitivity and frequent detection of inactive PTH fragments were recognized (13) . These assays are not used currently. The second-generation immunoradiometric assays were developed in the 1980s and were termed 'intact' PTH (i-PTH) assays ( Fig. 1) (9) . These assays use two different monoclonal antibodies: one is against the C-terminal region and the other against the N-terminal region (amino acids 1-34) (13) . This combination of antibodies was thought to confer perfect specificity for intact PTH (1-84) (14) . The i-PTH assays are widely used in present clinical practice. However, these assays recognize circulating fragments of PTH (13) , and some of these fragments, such as PTH (7-84), are active and may even be inhibitory (8) . This is of particular relevance in dialysis patients in whom such fragments accumulate and account for up to 45-50% of all circulating PTH molecular forms (15) (16) (17) (18) .
More recently, the third-generation assays have become available (13) . The third-generation assays use either a polyclonal antibody that exclusively recognizes whole PTH (1-84) or a combination of two monoclonal antibodies that recognize PTH and the N-terminal amino acids 1-4 of PTH ( Fig. 1 ) (19) (20) (21) . Thus, the third-generation assays are referred as 'whole PTH (w-PTH) assays' and provide much improved and ideal specificity for bioactive, full-length PTH (1-84).
We will further discuss the clinical application of both the i-PTH and w-PTH assays in the following sections.
METHODOLOGY AND SPECIFICITY OF TYPICAL INTACT PTH ASSAYS AND WHOLE PTH ASSAY
Methodology of typical i-PTH and w-PTH assays in Japan are as follows. The manufacturer's information on the PTH assays is summarized in Table 1 .
The Elecsys PTH assay is a second-generation 'i-PTH' assay that is a one-step sandwich electro-chemiluminescence immunoassay (ECLIA) technology (Fig. 1a) . This assay uses a biotinylated monoclonal antibody that binds to the N-terminal fragment (amino acid residues 1-37) and a ruthenium complex-labeled monoclonal antibody that binds to the C-terminal fragment (amino acid residues 38-84). These antibodies recognize the epitopes located in the regions of the amino acid residues 26-32 and 37-42, respectively. This assay, therefore, measures some of the PTH fragments lacking the N-terminal amino acids, such as PTH (7-84) fragments, as well (Fig. 1a) . In this regard, 'intact PTH' detected by the second-generation assays is not identical to full-length PTH. The Elecsys PTH (1-84) assay is a third-generation assay and also is a one-step sandwich ECLIA (Fig. 1b) . This assay uses a biotinylated monoclonal antibody against the N-terminal amino acids 1-5 and a ruthenium complex-labeled monoclonal antibody that reacts with the C-terminal amino acid residues 54-59. This assay specifically measures biologically intact PTH (1-84), but not PTH (7-84) fragments.
The ARCHITECT Intact PTH assay (CLIA intact PTH assay) is a third-generation two-step sandwich chemiluminescent immunoassay (CMIA) that uses a polyclonal antibody against full-length PTH. Fulllength PTH present in the sample binds to the anti-PTH antibody-coated paramagnetic microparticles. Then, these microparticles form a complex with an acridinium-labeled anti-PTH conjugate. Chemiluminescence is induced with pre-trigger and trigger solutions and is measured in relative light units (RLUs). The amount of full-length PTH in the sample is determined by the intensity of the RLUs detected by the ARCHITECT i System optics.
SAMPLING AND STORAGE CONDITIONS INFLUENCING THE MEASUREMENT OF PARATHYROID HORMONE IN BLOOD SAMPLES
Parathyroid hormone is relatively unstable: optimization of pre-analytical conditions, including specimen type, sampling time and storage conditions, is essential. Hanon E A recommend that blood samples for PTH measurement should be taken into tubes containing EDTA, ideally between 10:00 and 16:00, and plasma separated within 24 h of venepuncture. Plasma samples should be stored at 4
C and analyzed within 72 h of venepuncture. Particular regard must be paid to the venepuncture site when interpreting PTH concentration. Further research is required to clarify the suitability of freezing samples prior to PTH measurement (22) .
CLINICAL USEFULNESS AND PROBLEMS OF PTH ASSAYS IN MANAGEMENT OF MBD IN CKD PATIENTS

Intact PTH assay
Many clinical studies have reported PTH measurements determined by the i-PTH assays in patients with CKD. International clinical studies have demonstrated that both total mortality and risk of cardiovascular events tend to increase at i-PTH values of 300 pg/mL and higher, and these risks increase significantly at or above 600 pg/mL (23) . These findings indicate the validity of this method.
One report stated that survival prognosis worsens with high serum i-PTH levels (24), and another report described that survival prognosis can be improved by lowering i-PTH levels through medication (25, 26) . Parathyroidectomy (PTx), the most effective intervention for lowering PTH, can improve survival prognosis as well (27) (28) (29) . When survival outcomes with PTx were analyzed in patients with i-PTH values of 500 pg/mL or higher using the Japanese Society for Dialysis Therapy (JSDT) data, it was revealed that 1-year all-cause and cardiovascular mortality decreased by 34% and 41%, respectively (30) . Thus, lowering i-PTH levels can improve survival prognosis.
In a study on bone fractures, another clinical consequence of CKD-MBD, Jadoul et al. reported that all-fracture risk was 1.72 times greater in patients As discussed above, data from clinical studies using the i-PTH assays are accumulating, and i-PTH management has been recognized as a key to better outcomes in CKD-MBD patients. However, several issues concerning the i-PTH assays have been raised. One issue is that the true PTH activity may not be monitored by the i-PTH assays because the i-PTH assays also measure PTH fragments other than the full-length PTH (1-84), depending on the regions of PTH molecule that the assays recognize. Another issue concerns the existence of multiple i-PTH readout systems. A significant variation can be seen when the same sample is measured with different i-PTH assay kits using different readout systems. Although the results of different i-PTH assays generally correlate well with each other, there was significant discrepancy between the i-PTH assays in i-PTH concentrations in CKD patients (34) (35) (36) (37) (38) (39) .
Since multiple i-PTH assays are used in Japan, problems may arise when comparing data gathered at different institutions or from the same patients treated at different institutions. In fact, assays other than the ECLIA method are used for in-facility measurements in Japan as well. Figure 2 displays the correlation between i-PTH values measured via the ECLIA and CLIA methods in 290 dialysis patients. A satisfactory correlation coefficient (0.989) was found between the ECLIA and CLIA methods; but, the CLIA method produced approximately 30% higher values than those by the ECLIA method. These findings are consistent with La'ulu et al. (36) . Although it is possible to adjust this ratio to 1:1 by applying the correction formula, notating factors such as a normal upper limit multiplier would be necessary.
Whole PTH assay W-PTH measurement by the third-generation assays is ideal because these assays exclusively measure full-length PTH (1-84) . However, currently available clinical evidence is rather limited compared to that of i-PTH values, due primarily to its infrequent clinical applications. This might be the reason why i-PTH, not w-PTH is still used now as a standard PTH measurement in CKD-MBD patients.
A survey evaluated the prognosis of dialysis patients according to different types of PTH assay, including the w-PTH, i-PTH and PTH 7-84 assays. Results revealed a significant correlation between w-PTH values and the most favorable survival prognoses. The CHOICE study observed 515 hemodialysis patients for 35 months and showed that patients were at a greater risk of mortality when they had w-PTH > 160 pg/mL than when w-PTH was 60-160 pg/mL (hazard ratio, 1.62; 95% confidence interval, 1.03-2.54). However, no such effect on survival was revealed with the values of i-PTH, PTH 7-84, or PTH 1-84/7-84 (40) .
Notable inter-method variations were found in the PTH assays used in Japan (41). The results of the second-and third-generation PTH assays correlated highly with those of the second-generation assay of Scantibodies Laboratory as standard. The values obtained with the third-generation assays were approximately 60% of those with the secondgeneration assays; however, this ratio of the values may vary from one patient to another. The values obtained with the third-generation w-PTH assays were approximately 60% of those with the secondgeneration assays; however, this ratio of the values may vary from one patient to another. These findings agree with the opinion that the third-generation PTH assays are the method of choice to standardize the PTH measurement (41). The above studies made it clear that the third-generation w-PTH assays are useful to monitor CKD-MBD management. Yet, the target range of w-PTH values is not established in both Japanese and international guidelines. The target PTH values recommended in the current guidelines need to be changed based on values assessed by the third-generation assays.
CORRELATION OF SERUM PTH VALUES OBTAINED WITH I-PTH ASSAYS AND THOSE OBTAINED WITH W-PTH ASSAY
I-PTH values produced by the second-generation PTH assays are generally higher than those by the third-generation PTH assays (42) (43) (44) and are rarely lower than the third-generation assay values in patients with parathyroid carcinoma, severe primary or secondary hyperparathyroidism (45) (46) (47) (48) (49) (50) (51) (52) , because the second-generation assays also detect non-(1-84) fragments containing the N-terminus of PTH (43, 44) . In these patients, HPLC fractionation of serum revealed overproduction of an unusual form of PTH with an intact N-terminus but distinct from full-length PTH (1-84) (45) (46) (47) (48) . This amino-terminal form of PTH is readily detectable by the thirdgeneration PTH assays, but is poorly detectable by the second-generation PTH assays, presumably due to a post-translational modification of the amino acid 15-20 region that is necessary for the detection by the second-generation assays (34) (35) (36) (37) . Since the amino-terminal form of PTH accounts for less than 15% of w-PTH in healthy individuals (46) , increases in the ratio of the third-generation to the secondgeneration values indicate overproduction of the amino-terminal form of PTH in these patients. The amino-terminal form of PTH as well as other PTH fragments may contribute to the inter-method variability of PTH assays (19) because the detectability of the amino-terminal form of PTH may vary between the PTH assays (19) . The difference between i-PTH and w-PTH values is also affected by renal function. Both w-PTH and i-PTH values were reduced in dialysis patients and increased when glomerular filtration rate (GFR) exceeded 80 mL/min (53) . It was also found that both w-PTH and i-PTH values were reduced in secondary hyperparathyroidism (SHPT) patients who received maxacalcitol and cinacalcet (54, 55) . It is possible that the use of i-PTH may result in overestimation of parathyroid gland function.
GUIDELINES FOR CLINICAL APPLICATION OF SERUM PTH VALUES
Following the publication of the JSDT Clinical Practice Guidelines for the Management of SHPT in 2006 (Table 2) , the guideline members assessed the target i-PTH values for 3-year survival prognosis (56, 57) . Survival prognosis tended to worsen at i-PTH levels of 240 pg/mL or higher, and this effect was significantly pronounced at values of 300 pg/mL or higher. Based on the above findings, the 2012 JSDT CKD-MBD clinical practice guidelines recommend that attending physicians aim to maintain i-PTH levels between 60-240 pg/mL (58). The therapeutic target PTH values used in Japan are the lowest among the various guidelines. This implies that kidney transplantations are uncommon among a majority of long-term dialysis patients in Japan and that there is a belief that high PTH values should not be left unchecked. Indeed, PTH values iPTH > 500 pg/mL (resistance to medication) KDIGO (60) (2017)
Normal limit Normal limit
Two to nine times the upper normal limit for the assay resistance to medication in Japanese patients are actually maintained at a lower level (59) . In contrast, the KDIGO guidelines recommend maintaining PTH levels in the range of approximately two to nine times the upper normal limit for the i-PTH assay in patients with CKD stage 5D (60). The KDIGO guidelines also suggest that marked changes in PTH levels in either direction within this range prompt initiation or a change in therapy to avoid progression to levels outside of this range.
The upper limit of i-PTH levels in the KDIGO guidelines is approximately 600 pg/mL, allowing a broader range than the JSDT's recommendations. One reason for this difference is that multiple assay kits are in use in Europe and the United States, which would inevitably call for several different target values. By contrast, a majority of medical facilities in Japan use the ECLIA method to measure i-PTH and, as such, the JSDT guidelines can specify target i-PTH values. The target serum PTH levels recommended in the K/DOQI guidelines are based on the Nichols Allegro Intact PTH assay (61) . Now that this assay is no longer commercially available, it has been replaced by several i-PTH assay kits. These assays are widely used to evaluate parathyroid function and bone turnover in dialysis patients. However, recent studies have reported a marked inter-method variability in the evaluation of circulating PTH levels measured using these assay kits (38, 39) .
CURRENT TOPICS IN PTH MEASUREMENTS
To date, the discussion on CKD-MBD management has centered on quantities, such as i-PTH or w-PTH concentrations. However, recent studies are focused on the changes in the structure and quantities of PTH. Hocher et al. reported that the 8, 18 methionine residue of PTH 1-84 was oxidized. PTH increases blood calcium by activation of PTH 1 receptor, showing high levels in the bone and kidney. The second PTH receptor (PTH 2 receptor) is expressed mainly in the central nervous system, pancreas, testis, and placenta. The half-life of PTH is approximately 4 min. Oxidation of PTH at methionine residues 8 and/or 18 results in the loss of its biological activity (62) (63) (64) (65) . Classical third-generation PTH sandwich assays do not differentiate between biologically active nonoxidized PTH (n-oxPTH) and biologically nonactive oxidized PTH (oxPTH). Tepel et al. successfully distinguished ox PTH and n-ox PTH using antibodies that react with oxidized 8, 18 methionine (66). The majority of w-PTH present during actual measurement of patients' serum was n-oxPTH. Clinically, an examination of a group of 340 patients with a low median PTH value (105 pg/mL) controlled through hemodialysis found that, although patients with high w-PTH had favorable survival prognoses, the influence of n-ox PTH was minimal. Relationships between ox PTH, unfavorable survival prognosis and the properties of PTH are areas for future studies.
There is also ongoing debate about the effect of changes in PTH over specific time periods on survival prognosis. In a 12-month observational study of a group of patients with a median i-PTH value of 205 pg/mL controlled through hemodialysis, patients were grouped according to the magnitude of change in PTH (ΔPTH), and 12-month survival was monitored. They report in prevalent hemodialysis patients with median baseline iPTH values within the guideline recommended range, a decrease in ΔiPTH was associated with higher mortality (67) . Factors to be considered include nutritional status other than parathyroid gland function as well as other reported findings including better survival prognoses for patients in whom high PTH was lowered by PTx.
CONCLUSION AND FUTURE PERCEPTIVE
Currently the number of patients with ESRD is increasing despite advances in management and treatments. A majority of these patients have MBD. Measurement of circulating PTH levels is essential for proper and optimal management of MBD in CKD patients. Several different PTH assays have been developed and used in clinical practice. Of these assay methods, the i-PTH assays have been widely used in clinical practice and their usefulness has been confirmed based on a huge volume of clinical data. Many guidelines available at present recommend the i-PTH assays for evaluation of serum PTH levels in patients with MBD. Limitations of the i-PTH assays include measuring fragments other than full-length PTH (1-84) and data variation among different assay systems.
The w-PTH assay has been developed to avoid the above-mentioned deficits of the i-PTH assays. The w-PTH assay developed as the third generation is theoretically an ideal measurement because it is capable of accurately recognizing full-length PTH . Studies supporting the superiority of the w-PTH assays to the i-PTH assays have been reported. However, clinical data are not yet sufficient to firmly establish the advantages of w-PTH assays. In order for the w-PTH assay to be accepted by clinicians and investigators as the method of choice to evaluate serum PTH levels and as a standard method in guidelines, it is very important to carry out high quality clinical studies on the w-PTH assays in large cohorts of patients with end stage CKD.
Several guidelines, either national or international, have been published for clinical application of serum PTH levels. The target PTH values for proper management of ESRD patients are different in these guidelines. One of the international guidelines recommends rather wide ranges of serum PTH levels for management of CKD-MBD. On the other hand, the Japanese guidelines recommend strict control of serum PTH levels in a narrower range. This difference may originate from two reasons: one is that different PTH assays are being used and the other is that the concepts of treatment and management of the disease are different between these guidelines.
In future, we need to discuss whether internationally acceptable guidelines are desirable. If we find it desirable, we will have to select the most reliable PTH assay, standardize the assay method and establish global standard guidelines for CKD-MBD treatment. The new findings relating to PTH measurements and their clinical application described in the above current topics section should be carefully evaluated.
